Apimeds Pharmaceuticals US APUS
NYSE APUS
$3.30 -0.20 (-5.65%)
As of: Oct 20, 2026 · 12:58 PM EDT

Apimeds Pharmaceuticals US (APUS) Net Cash Flow (2024 - 2025)

Updated

Apimeds Pharmaceuticals US (APUS) reported Net Cash Flow of -$5.35 million for Q4 2025, compared with -$23,116 a year earlier.

Analysis

Apimeds Pharmaceuticals US (APUS) Net Cash Flow (2024 - 2025) Analysis & Trends

For FY2025, Apimeds Pharmaceuticals US posted Net Cash Flow of $1.63 million.

  • By year, Net Cash Flow came in at -$407,026 in FY2024 and $404,310 in FY2023.
  • The Q4 2025 figure ranks as the lowest quarterly Net Cash Flow in data going back to Q1 2024.
  • Per Business Quant data, the three quarters before Q4 2025 came in at -$1.75 million (Q3 2025), $8.5 million (Q2 2025) and $246,887 (Q1 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF (Qtr)
1 Eli Lilly 1,153.61 Bn 1,122.20 Bn 19.71 Bn 3.72 Bn
2 Johnson & Johnson 624.26 Bn 542.79 Bn 17.26 Bn -1.27 Bn
3 AbbVie 512.23 Bn 485.34 Bn 12.70 Bn -2.82 Bn
4 Merck 365.41 Bn 319.79 Bn 12.21 Bn 1.53 Bn
5 Novartis Ag 297.24 Bn 261.23 Bn 11.24 Bn 757.00 Mn
6 Astrazeneca 261.35 Bn 235.03 Bn 12.86 Bn -3.94 Bn
7 Amgen 234.57 Bn 189.97 Bn 7.24 Bn 1.95 Bn
8 Gilead Sciences 192.81 Bn 167.01 Bn 6.22 Bn -4.43 Bn
9 Pfizer 171.68 Bn 118.33 Bn 10.94 Bn -722.00 Mn
10 Apimeds Pharmaceuticals US 5.65 Mn -13.98 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -5.35 Mn
Sep 30, 2025 -1.75 Mn
Jun 30, 2025 8.50 Mn
Mar 31, 2025 246,887.00
Dec 31, 2024 -23,116.00
Sep 30, 2024 -36,755.00
Jun 30, 2024 -184,055.00
Mar 31, 2024 -263,100.00
API Access

Apimeds Pharmaceuticals US Net Cash Flow API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-cash-flow&ticker=APUS&period=max&api_key=YOUR_API_KEY